The new blood test that flagged heart attacks a decade before symptoms.
Three preprints, four outside cardiologists, and one still-pending FDA decision. We walked through every dataset.
Reviewed by Dr. R. Mehta, MD · 6 min read
Lead Briefing · Reviewed by Dr. Rohan Mehta, MD
A routine blood test is now predicting heart attacks a decade early. The FDA is still deciding what to do about it.
Three independent research teams reported the same biomarker signal this week. We read every preprint, spoke with four cardiologists who weren't involved, and checked the FDA's silent docket. Here is what is actually known, what isn't, and what your doctor is likely to bring up at your next visit.
This week's briefings
Four pieces that passed peer review.
Every article on VitalScope is read by at least one board-certified clinician before publication. Citations link back to PubMed, Cochrane, or the relevant regulator. Here is a slice of what shipped this week.
The seed-oil debate finally met a randomized trial — the result surprised both sides.
A 14-month, 612-person study puts linoleic acid head-to-head with saturated fat on inflammatory markers. The "seed oils are poison" thesis did not survive.
Reviewed by Dr. A. Okafor, MD, MPH · 7 min read
What the largest SSRI tapering study of the decade actually found.
Twenty-three percent of long-term users reported withdrawal lasting more than a month. The protocol the study used is now the one UK regulators recommend.
Reviewed by Dr. S. Chen, MD · 9 min read
Why this winter's flu vaccine was matched worse than any year since 2019.
WHO selection data, two months early, showed the drift. The mismatch wasn't a surprise — what happens next might be.
Reviewed by Dr. P. Brennan, MD · 5 min read
By the numbers
An editorial operation, not a content farm.
4.7M
monthly readers across 142 countries, verified by Similarweb (Oct 2025).
42
board-certified MDs and PhDs on the editorial board who peer-review every article before publication.
1,184
corrections logged publicly since launch — 96% caught before readers noticed.
$8.4M
in pharma and supplement advertising declined since 2019 to preserve editorial independence.
All figures independently verifiable. Corrections published at /corrections. Methodology reviewed annually by our editorial board.
What we got wrong, and how we fixed it
Three recent corrections from the public log.
We publish every substantive correction, no matter how small, in a publicly searchable archive. Three from this month, verbatim.
-
An earlier version stated that myopathy occurred in 12.4% of patients over 75 on high-dose atorvastatin. The correct figure, drawn from the 2024 Cochrane review (RR 1.09, 95% CI 1.02–1.17), is closer to 3.1% for symptomatic myopathy and 0.4% for rhabdomyolysis. We regret the error.
-
A paragraph implied that the Apple Watch AFib algorithm had FDA clearance for screening asymptomatic adults. It does not — clearance covers notification of suspected AFib in users who self-test, not population screening. The article has been reworded and the FDA 510(k) number linked inline.
-
We misattributed the 2023 NEJM trial to Imperial College London. The trial was conducted by the University of Birmingham and the NHS. Authorship and funding statement corrected; no findings changed.
Browse by section
Seven editorial desks. One standard of review.
-
01
Cardiology
48 briefings this year
-
02
Nutrition
31 briefings this year
-
03
Mental Health
27 briefings this year
-
04
Oncology
19 briefings this year
-
05
Pediatrics
14 briefings this year
-
06
Public Health
22 briefings this year
-
07
Longevity
11 briefings this year
-
08
Pharmacy & Drugs
9 briefings this year
Recognized by
Third-party validation, named.
We cite our sources; here are the institutions and awards that cite us.
-
2024
Sigma Awards
Data-journalism prize for our investigation into supplement-industry trial retractions.
-
Since 2019
HONcode certification
Recertified every two years. One of 31 U.S. health sites currently certified.
-
2023
Nieman Lab citation
Referenced in their study on health literacy for a 4.2-minute average reading time vs. 8.7 for peers.
-
Ongoing
380+ hospital systems
Approved as a patient-education resource, including Mayo Clinic Network affiliates.
-
2019 – present
19 mainstream news outlets
Cited by The Atlantic, STAT, NPR, and others as a source on medical research.
-
Ongoing
2,400+ academic papers
Have cited VitalScope briefings in peer-reviewed literature since 2019.